Chang-Gung Memorial Hospital, Kaohsiung

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination Therapy	Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm	Not yet recruiting	Phase 2	2025-09-03		NCT07151326
Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET	digestive system neuroendocrine neoplasm	Enrolling by invitation	Phase 1 / Phase 2	2025-08-15		NCT05385861

Clinical trials